Repligen is a Waltham bioprocessing-tools franchise whose second-quarter print tests whether a proteins-and-analytics rebound can carry the equity while a large cell-therapy acquisition is still pending. Management described sequential acceleration and market outperformance, then used that order momentum to lift full-year organic growth and adjusted earnings guidance. The strategic overlay is the July agreement to buy BioLife Solutions, a biopreservation-media platform already specified into commercial cell-therapy workflows. The debate is not whether the quarter looked clean on adjusted metrics. It is whether the organic recovery is broad enough, and the BioLife close certain enough, to support a multiple that already treats both as durable.
Proteins advanced at a fifty percent clip and analytics grew more than 30%, while filtration barely advanced after the Polymem sale and a named gene-therapy program headwind. Adjusted operating income rose 55% even as GAAP operating profit stayed flat, so the quality of the earnings bridge is part of the story rather than a footnote. Cash and marketable securities stood at $810 million, enough to fund the cash slice of BioLife and still leave a buffer. Equipment revenue stayed muted even as book-to-bill moved well above parity, which means the order book is building for later periods rather than converting in the current quarter.
Reported sales reached $204 million, a 12% increase that still needed a guidance raise to argue the first half was not a one-quarter spike. Europe, the Middle East, and Africa declined on a tough comparison while Asia Pacific led and North America grew in the high teens. The open question is whether Proteins and Analytics stay this hot after the BioLife shares hit the register, or whether filtration lag, unremediated control weaknesses, and deal dilution pull the multiple back toward a more ordinary tools company.